Clinical Trial Update: Study of Tamoxifen Dose Escalation in Breast Cancer Patients With CYP2D6 Polymorphisms [NA]

View source ↗

Summary

A completed study evaluating escalating doses of tamoxifen in breast cancer patients with CYP2D6 polymorphisms.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Tamoxifen (tamoxifen)

Snippet

Sponsor: Western Sydney Local Health District | Conditions: Breast Cancer, CYP2D6 Polymorphism | NA | Status: COMPLETED